It’s called PAZ320 and is a non-systemic, non-toxic, chewable drug candidate for people with Type 2 diabetes to better manage their blood sugar.
The compound, which is undergoing testing in clinical trials, is being developed by pharmaceutical company Boston Therapeutics.
David Platt, an expert in carbohydrate chemistry and CEO of Boston Therapeutics, said: “Everyone needs to make better nutritional choices, but being human, that isn’t always what happens. That’s where PAZ320 might help. Taken before meals, clinical studies show that 45% of the study group showed an average 40% reduction in blood glucose levels after meals.”
If it is approved by the FDA, PAZ320 may one day become an option to consider for people living with diabetes.
The American Heart Association (AHA) advises that for most men and women, sugar consumption should be capped at 150 and 100 calories per day, respectively.
© FoodBev Media Ltd 2024